Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics develops, manufactures and markets specialty plasma-derived biologics, with news centered on its immune globulin portfolio led by ASCENIV and BIVIGAM. Company updates commonly cover FDA label and post-marketing developments for ASCENIV, primary humoral immunodeficiency indications, product revenue trends, U.S. immune globulin market conditions, and distribution arrangements.
Recurring announcements also address plasma collection and biomanufacturing operations, commercial expansion, cash generation, share repurchases, capital-structure priorities and pipeline updates such as SG-001. ADMA's business updates link manufacturing yield, raw plasma supply, distributor inventory and product demand to its financial results.
ADMA Biologics (Nasdaq: ADMA) reported preliminary unaudited FY2025 revenue of $510–511 million, year-end cash of ~$88 million, and estimated $40 million of 4Q2025 operating cash flow. The company reiterated FY2025 adjusted EBITDA and adjusted net income guidance and raised FY2026 revenue and adjusted EBITDA targets to $635M and $360M, respectively, with FY2027 revenue and adjusted EBITDA expected at $775M and $455M. ADMA expects 2026 to be its first full year of yield-enhanced production, announced plasma center divestitures for $12M proceeds with long-term supply agreements, and plans an FDA pre-IND submission for SG-001 in 2026. Long-term targets include >$1.1B revenue and >$700M adjusted EBITDA by FY2029.
ADMA Biologics (Nasdaq: ADMA) announced that Adam Grossman, President and CEO, will deliver a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PT.
A live audio webcast will be available under Events & Webcasts in the company investor website and an archived webcast will be posted after the event.
ADMA (Nasdaq: ADMA) reported 3Q 2025 revenue $134.2M (+12% YoY), GAAP net income $36.4M, and Adjusted EBITDA $58.7M (+29% YoY). The company received FDA lot release for its first yield‑enhanced production batches, expected to drive gross margin expansion beginning in 4Q 2025 and through 2026. ASCENIV showed record utilization and a retrospective analysis reported infections falling from 2.1 to 0.9 per year (p<0.05). ADMA raised FY2025 revenue guidance to $510M+, FY2026 to $630M+, reaffirmed FY2025 Adjusted EBITDA at $235M, and raised FY2026 Adjusted EBITDA to $355M+. Company cites disciplined capital deployment, ongoing share repurchases, and SG‑001 pipeline upside.
ADMA Biologics (Nasdaq: ADMA) will report third quarter 2025 financial results on November 5, 2025 after U.S. market close.
Management will host a live conference call and audio webcast on November 5, 2025 at 4:30 p.m. ET to discuss financial results and company updates. Participants must register to receive dial-in numbers and a unique PIN; joining ~10 minutes early is recommended. A live webcast will be available for listeners, and an archived replay will be posted under Events & Webcasts on the company investor site: https://ir.admabiologics.com/events-webcasts.
ADMA Biologics (Nasdaq: ADMA) reported strong Q2 2025 financial results with total revenue of $122.0 million, up 14% year-over-year (29% excluding prior year non-recurring item). The company achieved GAAP net income of $34.2 million and Adjusted EBITDA of $50.8 million.
Key developments include initiating commercial-scale manufacturing with an FDA-approved yield enhancement process delivering 20%+ increase in finished IG output, securing a $300 million syndicated debt refinancing led by J.P. Morgan, and expanding operations with a new Boca Raton facility acquisition that could increase cGMP manufacturing space by up to 30%.
ADMA reaffirmed its guidance, projecting FY 2025 revenue over $500 million and FY 2026 revenue of $625+ million. The company expects to reach $1.1+ billion in annual revenue before 2030.
ADMA Biologics (NASDAQ: ADMA), a U.S.-based biopharmaceutical company focused on specialty biologics, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close.
The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. Participants must pre-register to receive dial-in information and a unique PIN. A replay of the webcast will be available in the investor section of ADMA's website.
ADMA Biologics reported strong Q1 2025 financial results with total revenue of $114.8 million, up 40% year-over-year. The company achieved GAAP Net Income of $26.9 million (51% YoY increase) and Adjusted EBITDA of $47.9 million (81% YoY increase). ADMA received FDA approval for its yield enhancement process, expected to increase production output by 20% from the same plasma volume.
The company increased its guidance for FY 2025 and 2026, projecting total revenues of $500+ million and $625+ million respectively. ADMA authorized a $500 million share repurchase program, representing 8% of current market capitalization. The company's debt reorganization reduced cost of debt capital by 1.1%. ADMA now expects to achieve $1.1 billion in annual revenues before 2030, with anticipated margin expansion.
ADMA Biologics (Nasdaq: ADMA), a U.S.-based commercial biopharmaceutical company focused on specialty biologics, has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after U.S. market close.
The company will host a live conference call and audio webcast at 4:30 p.m. ET on the same day. Participants must pre-register to receive dial-in numbers and a unique PIN, with recommended joining time being 10 minutes before the event start.
Two participation options are available:
- Interactive Q&A: Register to receive dial-in details and PIN
- Listen-only: Access the live webcast directly
An archived replay will be accessible in the investor section of ADMA's website under "Events & Webcasts."
ADMA Biologics (Nasdaq: ADMA) has received FDA approval for its innovative yield enhancement production process, marking a significant milestone for the biopharmaceutical company. The new process demonstrates an ability to increase production yields by approximately 20% from the same starting plasma volume, benefiting both ASCENIV and BIVIGAM products.
As the first U.S. producer of plasma-derived products to achieve this regulatory approval, ADMA expects meaningful acceleration in revenue and earnings trajectory beginning in late 2025 and accelerating into 2026. The company's internal R&D platform continues to advance, with ongoing development of novel pipeline programs including SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia.
ADMA Biologics (Nasdaq: ADMA) has issued a statement emphasizing its strategic advantage as a fully U.S.-based biopharmaceutical company amid recent tariff implementations. The company confirms that the new tariffs on foreign goods, services, and manufacturing will have no impact on its operations due to its entirely domestic supply chain and manufacturing infrastructure.
The company's President and CEO, Adam Grossman, highlighted that all manufacturing operations, end-market sales, and customer engagements are conducted exclusively within the United States. ADMA's vertically integrated supply chain, entirely based in the U.S., provides complete domestic control over sourcing, manufacturing, and distribution, aligning with increasing federal and private sector preferences for U.S.-made products.